Krystal Biotech, Inc.
KRYS
$137.87
-$3.34-2.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 359.21M | 333.45M | 290.51M | 241.52M | 166.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 359.21M | 333.45M | 290.51M | 241.52M | 166.23M |
| Cost of Revenue | 23.83M | 22.67M | 20.06M | 17.98M | 11.52M |
| Gross Profit | 335.38M | 310.78M | 270.45M | 223.54M | 154.71M |
| SG&A Expenses | 127.88M | 120.35M | 113.69M | 107.16M | 102.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 207.41M | 199.89M | 187.32M | 176.57M | 162.21M |
| Operating Income | 151.80M | 133.56M | 103.19M | 64.95M | 4.03M |
| Income Before Tax | 168.75M | 138.02M | 95.36M | 57.40M | 108.38M |
| Income Tax Expenses | 22.03M | 14.06M | 6.20M | 5.03M | 2.44M |
| Earnings from Continuing Operations | 146.73 | 123.96 | 89.16 | 52.37 | 105.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.73M | 123.96M | 89.16M | 52.37M | 105.94M |
| EBIT | 151.80M | 133.56M | 103.19M | 64.95M | 4.03M |
| EBITDA | 153.16M | 135.91M | 105.66M | 68.04M | 7.52M |
| EPS Basic | 5.09 | 4.31 | 3.11 | 1.83 | 3.77 |
| Normalized Basic EPS | 3.93 | 3.55 | 2.90 | 2.08 | 0.73 |
| EPS Diluted | 4.93 | 4.17 | 3.00 | 1.77 | 3.65 |
| Normalized Diluted EPS | 3.80 | 3.41 | 2.79 | 2.00 | 0.70 |
| Average Basic Shares Outstanding | 115.20M | 114.88M | 114.36M | 113.78M | 113.10M |
| Average Diluted Shares Outstanding | 119.41M | 119.29M | 118.71M | 117.65M | 116.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |